Literature DB >> 12804771

Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation.

Kaoru Takeuchi1, Shin-ich Kadota, Makoto Takeda, Naoko Miyajima, Kyosuke Nagata.   

Abstract

Measles virus (MV), a member of the family Paramyxoviridae, encodes C and V non-structural proteins. To clarify the functions of MV C and V proteins, HeLa cell lines constitutively expressing C or V protein were established. We found that expression of V protein inhibited interferon (IFN)-alpha/beta signaling but not IFN-gamma signaling. C protein had no inhibitory effect on IFN signaling in our experimental condition. Degradation of selective signal transducers and activators of transcription (STAT) proteins was not observed in HeLa cells expressing V protein. In contrast, tyrosine phosphorylation of both STAT1 and STAT2 was inhibited in these cells after IFN-beta stimulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804771     DOI: 10.1016/s0014-5793(03)00528-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  87 in total

1.  Identification of the nuclear export signal and STAT-binding domains of the Nipah virus V protein reveals mechanisms underlying interferon evasion.

Authors:  Jason J Rodriguez; Cristian D Cruz; Curt M Horvath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Differential cellular immune responses to wild-type and attenuated edmonston tag measles virus strains are primarily defined by the viral phosphoprotein gene.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Neelam Dhiman; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  J Med Virol       Date:  2010-11       Impact factor: 2.327

Review 3.  Paramyxovirus disruption of interferon signal transduction: STATus report.

Authors:  Aparna Ramachandran; Curt M Horvath
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

4.  A highly attenuated measles virus vaccine strain encodes a fully functional C protein.

Authors:  Yuichiro Nakatsu; Makoto Takeda; Masaharu Iwasaki; Yusuke Yanagi
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

5.  Foot-and-mouth disease virus structural protein VP3 degrades Janus kinase 1 to inhibit IFN-γ signal transduction pathways.

Authors:  Dan Li; Jin Wei; Fan Yang; Hua-Nan Liu; Zi-Xiang Zhu; Wei-Jun Cao; Shu Li; Xiang-Tao Liu; Hai-Xue Zheng; Hong-Bing Shu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 6.  Paramyxovirus evasion of innate immunity: Diverse strategies for common targets.

Authors:  Michelle D Audsley; Gregory W Moseley
Journal:  World J Virol       Date:  2013-05-12

7.  Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.

Authors:  Jayson Hardcastle; Lisa Mills; Courtney S Malo; Fang Jin; Cheyne Kurokawa; Hirosha Geekiyanage; Mark Schroeder; Jann Sarkaria; Aaron J Johnson; Evanthia Galanis
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

8.  Measles virus circumvents the host interferon response by different actions of the C and V proteins.

Authors:  Yuichiro Nakatsu; Makoto Takeda; Shinji Ohno; Yuta Shirogane; Masaharu Iwasaki; Yusuke Yanagi
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

9.  Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys.

Authors:  Patricia Devaux; Gregory Hodge; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

10.  Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma.

Authors:  Xin Meng; Takafumi Nakamura; Toshihiko Okazaki; Hiroyuki Inoue; Atsushi Takahashi; Shohei Miyamoto; Gaku Sakaguchi; Masatoshi Eto; Seiji Naito; Makoto Takeda; Yusuke Yanagi; Kenzaburo Tani
Journal:  Mol Ther       Date:  2010-01-05       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.